Use of anakinra in severe COVID-19: A case report

Int J Infect Dis. 2020 Jul:96:607-609. doi: 10.1016/j.ijid.2020.05.026. Epub 2020 May 11.

Abstract

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).

Keywords: Anakinra; Biologic; COVID-19; IL-1; Treatment.

Publication types

  • Case Reports

MeSH terms

  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / drug therapy*
  • Cytokine Release Syndrome / drug therapy
  • Cytokine Release Syndrome / virology
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2

Substances

  • Interleukin 1 Receptor Antagonist Protein